Essential Pharma
Manufacturing · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
8a Crabtree Rd, Thorpe Ward, Surrey, TW2...Phone Number
+44 1784477167Website
www.essentialpharmagroup.comRevenue
$35.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Essential Pharma
Essential Pharma is a specialist pharmaceutical company dedicated to ensuring access to essential medicines, particularly for small, underserved, or rare disease populations. The company focuses on developing and delivering high-quality therapies, including those at risk of discontinuation, across various therapeutic areas such as rare diseases, CNS, ophthalmology, and gastroenterology. With a growing portfolio of products available in approximately 70 countries, Essential Pharma aims to address significant unmet medical needs. Their commitment to corporate responsibility and innovation drives their mission to transform lives through reliable healthcare solutions.Explore more
Essential Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Essential Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Essential Pharma recently announced quarterly report
Funding: Get notified immidiatlly once Essential Pharma has new funding data
Essential Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Essential Pharma
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Essential Pharma had a recent Job posting/layoffs
Check if Essential Pharma has recently received funding, and reach out quickly before it becomes old news!
Check out if Essential Pharma is spiking on competitors!
Product Launch: Get notified when Essential Pharma launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Essential Pharma
Compare insights from companies similar to Essential Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Essential Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Essential Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Essential Pharma.
Essential Pharma financials insights
Gather financial insights about Essential Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Unspecified
$936M
Essential Pharma Tech Stack
A closer look at the technologies used by Essential Pharma
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
New Hire
Executive Move
Executive Moves, New Hire
Essential Pharma News & Media
Essential Pharma 旗下公司 Renaissance Pharma Limited 用于治疗高危神经母细胞瘤的 Daretabart (hu1418K322A) 获得 FDA 快速通道认定，并通过 IND 审评
英国 – 2026 年 4 月 21 日 – Essential Pharma 旗下专注于研发阶段资产的公司 Renaissance Pharma Limited 今天宣布，美国食品和药品管理局 (FDA) 已授予其新型抗 GD2 单克隆抗体 Daretabart (hu1418K322A) 快速通道认定资质，这种正在开发的药物用于治疗罕见儿童癌症 — 高危神经母细胞瘤 (HRNB)。此项认定旨在解决 HRNB 领域存在的重大未满足医疗需求，将有助于该公司在研发过程中与 FDA 更频繁地沟通互动，并使其具备获得加速审评和滚动审评的资格。Renaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastoma
UK – 14 April 2026 – Renaissance Pharma Limited, an Essential Pharma company focused on development stage assets, today announces that the US Food and Drug Administration (FDA) has granted Fast Track Designation for Daretabart (hu1418K322A), a novel anti-GD2 monoclonal antibody in development for the treatment of high-risk neuroblastoma (HRNB), a rare paediatric cancer. The designation recognises the significant unmet medical need in HRNB and will support more frequent interactions with the FDAEssential Pharma strengthens rare disease portfolio with acquisition of Ventavis® (iloprost trometamol) for adult primary pulmonary hypertension
Egham, UK – 17 February 2026 – Essential Pharma (“Essential” or “the Company”), a global specialty pharmaceutical company, today announces the acquisition of Ventavis® (iloprost trometamol) from Bayer AG, including rights to the accompanying Breelib® nebuliser delivery technology.UK: Essential Pharma appoints CFO and CTO to accelerate growth - Investors in Healthcare
Essential Pharma appoints CFO and CTO to accelerate growth
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Essential Pharma
Sign Up For FreeTo access detailed company insights
Essential Pharma is a specialist pharmaceutical company dedicated to ensuring access to essential medicines, particularly for small, underserved, or rare disease populations. The company focuses on developing and delivering high-quality therapies, including those at risk of discontinuation, across various therapeutic areas such as rare diseases, CN... Read More
